Intraocular pressure response to topical β-blockers associated with an ADRB2 single-nucleotide polymorphism

被引:25
作者
McCarty, Catherine A. [1 ]
Burmester, James K. [1 ]
Mukesh, Bickol N. [2 ]
Patchett, Richard B. [3 ]
Wilke, Russell A. [1 ,4 ,5 ]
机构
[1] Marshfield Clin Fdn Med Res & Educ, Ctr Human Genet, Marshfield, WI 54449 USA
[2] Marshfield Clin Fdn Med Res & Educ, Biomed Informat Res Ctr, Marshfield, WI 54449 USA
[3] Marshfield Clin Fdn Med Res & Educ, Dept Ophthalmol, Marshfield, WI 54449 USA
[4] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA
[5] Med Coll Wisconsin, Dept Pharmacol, Milwaukee, WI 53226 USA
关键词
D O I
10.1001/archopht.126.7.959
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Objectives: To determine whether candidate pharmacodynamic (P-adrenergic receptor) and pharmacokinetic (cytochrome P450 2D6) gene polymorphisms are associated with the intraocular pressure (IOP) response to topical beta-blockers. Methods: Medical records of 18 773 adults in the Personalized Medicine Research Project were searched to extract all IOP measurements for subjects who had been prescribed a topical P-blocker. Five single-nucleotide polymorphisms in the beta(1)-, beta(2)-, and beta(3)-adrenergic receptor genes and 6 polymorphisms in the CYP2D6 gene were genotyped. Results: A total of 58.1% of the subjects were female; the mean age was 63.8 years. Topical beta-blockers were prescribed for 343 eyes of 215 subjects. An IOP reduction of 20% or more in I or both eyes was observed in 61.0% of subjects. Men were significantly more likely than women to have an IOP decrease of 20% or more (69.3% vs 54.9%, respectively; chi(2) = 4.48; P =.04). After adjusting for sex, family history of glaucoma, and use of systemic beta-blockers, subjects with the CC genotype at coding single-nucleotide polymorphism rs1042714 in the ADRB2 gene were significantly more likely to experience an IOP decrease of 20% or more (odds ratio, 2.00; 95% confidence interval, 1.00-4.02). Conclusion: We found that a coding single-nucleotide polymorphism in ADRB2 is associated with an increased likelihood of a clinically meaningful IOP response to topical beta-blockers. Clinical Relevance: Because topical beta-blockers are the least expensive class of agents used to lower IOP, genotype-based drug prescribing could save health care dollars.
引用
收藏
页码:959 / 963
页数:5
相关论文
共 38 条
[1]   CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants [J].
Bradford, LD .
PHARMACOGENOMICS, 2002, 3 (02) :229-243
[2]   β2-adrenoceptor gene polymorphisms [J].
Brodde, OE ;
Leineweber, K .
PHARMACOGENETICS AND GENOMICS, 2005, 15 (05) :267-275
[3]   TOPICAL TIMOLOL DECREASES PLASMA HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL LEVEL [J].
COLEMAN, AL ;
DIEHL, DLC ;
JAMPEL, HD ;
BACHORIK, PS ;
QUIGLEY, HA .
ARCHIVES OF OPHTHALMOLOGY, 1990, 108 (09) :1260-1263
[4]   Epidemiologic research in an integrated regional medical care system: The Marshfield Epidemiologic Study Area [J].
DeStefano, F ;
Eaker, ED ;
Broste, SK ;
Nordstrom, DL ;
Peissig, PL ;
Vierkant, RA ;
Konitzer, KA ;
Gruber, RL ;
Layde, PM .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1996, 49 (06) :643-652
[5]   The effect of common polymorphisms of the β2-adrenergic receptor on agonist-mediated vascular desensitization [J].
Dishy, V ;
Sofowora, GG ;
Xie, HG ;
Kim, RB ;
Byrne, DW ;
Stein, CM ;
Wood, AJJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (14) :1030-1035
[6]   Complex promoter and coding region β2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness [J].
Drysdale, CM ;
McGraw, DW ;
Stack, CB ;
Stephens, JC ;
Judson, RS ;
Nandabalan, K ;
Arnold, K ;
Ruano, G ;
Liggett, SB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (19) :10483-10488
[7]   PHARMACOGENETIC EXPLANATION FOR EXCESSIVE BETA-BLOCKADE FOLLOWING TIMOLOL EYE DROPS - POTENTIAL FOR ORAL-OPHTHALMIC DRUG-INTERACTION [J].
EDEKI, TI ;
HE, HB ;
WOOD, AJJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (20) :1611-1613
[8]  
Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
[9]  
Fuchsjager-Mayrl G, 2005, MOL VIS, V11, P811
[10]   AMINO-TERMINAL POLYMORPHISMS OF THE HUMAN BETA(2)-ADRENERGIC RECEPTOR IMPART DISTINCT AGONIST-PROMOTED REGULATORY PROPERTIES [J].
GREEN, SA ;
TURKI, J ;
INNIS, M ;
LIGGETT, SB .
BIOCHEMISTRY, 1994, 33 (32) :9414-9419